Soligenix Inc (NASDAQ:SNGX)

0.5629
Delayed Data
As of Jun 24
 -0.0391 / -6.50%
Today’s Change
0.38
Today|||52-Week Range
1.32
-14.75%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$22.0M

Company Description

Soligenix, Inc. is a late-stage biopharmaceutical company, which engages in the development and commercialization of products to treat rare diseases. It operates through the Specialized BioTherapeutics and Public Health Solutions segments. The Specialized BioTherapeutics segment focuses on the development of a novel photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible fluorescent light for the treatment of cutaneous T-cell lymphoma. The Public Health Solutions segment consists of active development programs for RiVax, a ricin toxin vaccine candidate, and SGX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease. The company was founded in 1987 and is headquartered Princeton, NJ.

Contact Information

Soligenix, Inc.
29 Emmons Drive
Princeton New Jersey 08540-5919
P:(609) 538-8200
Investor Relations:

Employees

Shareholders

Individual stakeholders8.32%
Mutual fund holders4.79%
Other institutional2.83%

Top Executives

Christopher J. SchaberChairman, President & Chief Executive Officer
Jonathan L. GuarinoChief Financial Officer, Secretary & Senior VP
Oreola DoniniChief Scientific Officer & Senior Vice President
Richard C. StraubeChief Medical Officer & Senior Vice President
Adam T. RumageVP-Regulatory Affairs & Project Management